Latest Breaking News On - மைக் ராப் - Page 3 : comparemela.com

Why Ardelyx Stock Is Sinking Today | The Motley Fool

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Ardelyx (NASDAQ:ARDX) were sinking 13% lower as of 11 a.m. EDT on Friday. The decline came after the company announced Thursday evening that the U.S. Food and Drug Administration (FDA) is pushing back its review period for tenapanor by three months. So what Ardelyx originally hoped for an FDA approval of tenapanor in controlling serum phosphorus in adults with chronic kidney disease (CKD) on dialysis by yesterday. However, the agency requested additional analyses to help it better understand the drug s mechanism of action.

Mike raabDrug administrationமைக் ராப்

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

More from AP

Mike raabFosun pharmaExchange commissionPrnewswire ardelyx incExchange commission onDrug administrationArdelyx incPrescription drug user fee actNew drug applicationKyowa kirinKnight therapeuticsPrivate securities reform actAnnual reportமைக் ராப்பரிமாற்றம் தரகுபரிமாற்றம் தரகு ஆன்

Ardelyx (ARDX) Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Ardelyx (ARDX) Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mike raabDrug administrationArdelyx incPrescription drug user fee actNew drug applicationமைக் ராப்ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம்புதியது மருந்து விண்ணப்பம்

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Mike raabFosun pharmaExchange commissionExchange commission onDrug administrationArdelyx incPrescription drug user fee actNew drug applicationKyowa kirinKnight therapeuticsPrivate securities reform actAnnual reportமைக் ராப்பரிமாற்றம் தரகுபரிமாற்றம் தரகு ஆன்ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம்

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3 Source: Streetwise Reports (4/15/21) Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. Biopharmaceutical company Ardelyx Inc. (ARDX:NASDAQ), which concentrates its efforts on the development of medicines to treat kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (4151:TSE) has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The firm noted that by Kyowa Kirin s moving forward into the various clinical trials, under the terms outlined in the agreement between the companies, Ardelyx is now entitled to receive a $5 million payment for reaching this important development milestone.

Mike raabStephen hythaFosun pharmaStreetwise reportsKyowa kirin co ltdDrug administrationArdelyx incKyowa kirinStreetwise reportமைக் ராப்கியோவா கிரீன் இணை லிமிடெட்கியோவா கிரீன்